A panel discussion on changing treatment landscape of diffuse large B-cell lymphoma (DLBCL) and how new data from ASH 2021 on CAR-T therapies and antibody-drug conjugate are likely to change frontline treatment and sequencing of therapies in relapsed and refractory DLBCL going forward.
Frontline Acalabrutinib/BR Regimen Significantly Improves PFS in Mantle Cell Lymphoma
Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed/Refractory CLL/SLL
Linvoseltamab Elicits Deep, Durable Responses in R/R Multiple Myeloma
Prospective Analysis Highlights Patterns of Progression to Myelofibrosis Following Essential Thrombocythemia Diagnosis
2 Commerce Drive
Cranbury, NJ 08512